RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons
Comment: A critical takeaway from this real-world data is the apparent lack of protection for oncology patients. The finding for the immunocompromised subgroup—which includes many patients with active cancer or on immunosuppressive therapy—is stark. A vaccine effectiveness of 30% that is not statistically significant (95% CI, -9% to 55%) means we cannot conclude there is […]